Coherus reported higher Q4 revenue driven by LOQTORZI growth, but operating losses remained large as R&D spending increased. The company continues transitioning toward an oncology-focused pipeline while reducing debt and maintaining a sizable cash position.

Coherus Oncology reported a net income of $297.767 million for Q2 2025, a significant improvement from a net loss in the prior year, primarily driven by the UDENYCA divestiture. Revenue from continuing operations remained stable at $10.254 million, with strong growth in LOQTORZI net product revenue.

Coherus delivered $7.6 million in net revenue from continuing operations in Q1 2025, primarily driven by LOQTORZI sales, and significantly reduced its GAAP and non-GAAP losses as it transitions to a focused oncology company.

Coherus' Q4 FY24 revenue declined 41% year-over-year to $54.1 million, primarily due to the divestiture of CIMERLI and YUSIMRY. Despite this, UDENYCA revenue grew 28% to $46.3 million, while LOQTORZI revenue increased 29% quarter-over-quarter. The company reported a net loss of $50.7 million and an EPS of -$0.44, reflecting increased investment in oncology development.

Coherus BioSciences reported net revenue of $70.8 million for Q3 2024, driven by a 30% increase in UDENYCA net revenue quarter-over-quarter and LOQTORZI revenue increased 50% quarter-over-quarter. The company's sharpened focus on oncology is delivering results, with Q3 2024 revenues comparable to Q3 2023, despite divestitures, and with higher gross profit, lower operating expenses and lower interest expense. The company is advancing its immuno-oncology pipeline to proof-of-concept studies in combination with toripalimab.

Coherus BioSciences reported net revenue of $65.0 million for Q2 2024, including $50.9 million from UDENYCA, $3.8 million from LOQTORZI, $3.8 million from YUSIMRY, and $6.5 million from other revenue. The company's net loss for the quarter was $12.9 million, or $(0.11) per share.

Coherus BioSciences reported a net revenue of $77.1 million for Q1 2024, which includes sales from UDENYCA, LOQTORZI, and YUSIMRY, while CIMERLI was divested during the quarter. The company achieved a net income of $102.9 million, or $0.83 per share on a diluted basis, compared to a net loss of $75.7 million in Q1 2023. Non-GAAP net loss was $35.8 million, or $(0.32) per share.

Coherus BioSciences reported a net revenue of $91.5 million for the fourth quarter of 2023. The company is focusing on driving revenues, reducing costs, and advancing its pipeline, with constant attention to long-term shareholder value. The divestiture of CIMERLI and debt paydown improves the company's capital structure and sharpens its focus on oncology.

Coherus BioSciences reported a 27% increase in net revenue compared to the prior quarter, reaching $74.6 million. CIMERLI sales increased by 50% to $40 million compared to the prior quarter. The company is lowering its revenue guidance for 2023 to a range of $250 to $260 million.

Coherus BioSciences reported an 81% increase in net revenue compared to the prior quarter, reaching $58.7 million. This growth was primarily driven by the quadrupling of CIMERLI® net sales to $26.7 million. The company launched the UDENYCA® autoinjector in late May and YUSIMRY™ in July. Additionally, a planned merger with Surface Oncology is expected to significantly advance the next-generation immuno-oncology pipeline.

Coherus BioSciences reported a net product revenue of $32.4 million for the first quarter of 2023. The company is preparing for multiple product launches and anticipates accelerated revenue growth for the remainder of 2023.

Coherus BioSciences reported net product sales of $45.4 million in Q4 2022, including $38.3 million from UDENYCA® and $6.9 million from CIMERLI®. The company is preparing for multiple product launches in 2023 and expects a return to profitability in 2024 through revenue growth and expense control.

Coherus BioSciences reported third quarter 2022 financial results, with UDENYCA® net sales of $45.4 million. CIMERLI™ was launched in the United States on October 3rd. The company is planning for 2023 commercial launches of toripalimab, YUSIMRY™ and UDENYCA® OBI. They are targeting a return to profitability in 2024.

Coherus BioSciences reported a decrease in net revenue for Q2 2022, primarily due to lower sales of UDENYCA®. However, the company is preparing for the launch of multiple new products in 2022 and 2023, including CIMERLI™, toripalimab, and YUSIMRY™.

Coherus BioSciences reported a net revenue of $60.1 million, primarily from UDENYCA® sales, and a net loss of $96.1 million for the first quarter of 2022. The company is preparing for multiple product launches and continues to invest in its immuno-oncology pipeline.

Coherus BioSciences reported a net revenue of $73.4 million for Q4 2021, a decrease from $110.4 million in the same period of 2020. The company experienced a net loss of $45.7 million, or $(0.60) per share, compared to a net income of $9.7 million, or $0.12 per share in Q4 2020. Despite the financial downturn, Coherus achieved key milestones, including FDA approval for YUSIMRY™ and BLA acceptance for CIMERLI™.

Coherus BioSciences reported third-quarter 2021 financial results, with net product revenue of $82.5 million. The company is focused on expanding its commercial product portfolio, with three BLAs under FDA review and multiple additional applications expected in 2022.

Coherus BioSciences reported second quarter 2021 financial results, with UDENYCA® net sales of $88 million. The company's GAAP net loss was $29.9 million, and non-GAAP net loss was $27.3 million. Coherus had cash, cash equivalents and marketable securities of $454.4 million as of June 30, 2021. The company is advancing its biosimilar and immuno-oncology pipeline, with multiple BLA submissions planned or under review.

Coherus BioSciences reported a GAAP net loss of $173 million, primarily driven by the $145 million upfront payment to Junshi Biosciences and one-time charges related to the termination of the CHS-2020 biosimilar program. Net product revenue was $83 million, and the company had cash, cash equivalents, and marketable securities of $400 million at the end of the quarter.

Coherus BioSciences reported Q4 2020 financial results, featuring $110 million in product revenues and a net income of $9.7 million. The company highlighted the strong performance of UDENYCA and progress in its biosimilar pipeline, including the collaboration with Junshi Biosciences for toripalimab.

Coherus BioSciences reported strong third-quarter results, driven by UDENYCA® net sales of $113.6 million. The company achieved a net income of $27.9 million, or $0.33 per share, and a non-GAAP net income of $39.7 million, or $0.47 per share. Coherus is focused on expanding its pipeline and addressable market.

Coherus BioSciences reported second-quarter 2020 financial results, including net product revenue of $135.7 million and net income of $59.0 million, or $0.70 per share on a diluted basis. Non-GAAP income for the quarter was $68.3 million, or $0.81 per share on a diluted basis.

Coherus BioSciences reported a strong financial performance for Q1 2020, marked by UDENYCA® net sales reaching $116.2 million and a net income of $35.6 million. The company's financial position was further strengthened by a convertible notes financing, supporting pipeline development and long-term growth.

Coherus BioSciences reported fourth-quarter net product revenue of $123.9 million and net income of $39.2 million, or $0.53 per share. The company's UDENYCA launch continued to drive strong results, achieving approximately 20.5% unit market share by year-end. Coherus also completed key licensing transactions to enhance its product pipeline and advanced its internal pipeline in ophthalmology and immunology.